|
主要作者
|
摘要标题
|
演示文稿详情 (CDT)
|
|
抗体偶联药物
|
|
Shitara, K
|
Trastuzumab deruxtecan (T-
DXd) vs ramucirumab (RAM) +
paclitaxel (PTX) in second-line
treatment of patients (pts) with
human epidermal growth factor
receptor 2-positive (HER2+)
unresectable/metastatic gastric
cancer (GC) or
gastroesophageal junction
adenocarcinoma (GEJA):
Primary analysis of the
randomized, phase 3
DESTINY-Gastric04 study.
|
Abstract #LBA4002
Oral Abstract Session
31 May 2025
3:24pm
|
|
Tolaney, SM
|
Trastuzumab deruxtecan (T-
DXd) + pertuzumab (P) vs
taxane + trastuzumab +
pertuzumab (THP) for first-line
(1L) treatment of patients (pts)
with human epidermal growth
factor receptor 2–positive
(HER2+) advanced/metastatic
breast cancer (a/mBC): Interim
results from DESTINY-Breast09.
|
Abstract #LBA1008
Oral Abstract Session
2 June 2025
7:30am
|
|
Dent, R
|
Exploratory biomarker analysis
of trastuzumab deruxtecan (T-
DXd) vs physician's choice of
chemotherapy (TPC) in HER2-
low/-ultralow, hormone
receptor-positive (HR+)
metastatic breast cancer (mBC)
in DESTINY-Breast06 (DB-06).
|
Abstract #1013
Oral Abstract Session
31 May 2025
3:23pm
|
|
Levy, BP
|
TROPION-Lung02:
Datopotamab deruxtecan
(Dato-DXd) plus
pembrolizumab (pembro) with
or without platinum
chemotherapy (Pt-CT) as first-
line (1L) therapy for advanced
non-small cell lung cancer (aNSCLC).
|
Abstract #8501
Oral Abstract Session
1 June 2025
8:12am
|
|
Waqar, SN
|
First-line (1L) datopotamab
deruxtecan (Dato-DXd) +
rilvegostomig in advanced or
metastatic non-small cell lung
cancer (a/mNSCLC): Results
from TROPION-Lung04 (cohort 5).
|
Abstract #8521
Poster Session
31 May 2025
1:30pm
|
|
肿瘤驱动因素和耐药性
|
|
Turner, NC
|
Camizestrant + CDK4/6
inhibitor (CDK4/6i) for the
treatment of emergent ESR1
mutations during first-line (1L)
endocrine-based therapy (ET)
and ahead of disease
progression in patients (pts)
with HR+/HER2– advanced
breast cancer (ABC): Phase 3,
double-blind ctDNA-guided
SERENA-6 trial.
|
Abstract #LBA4
Plenary Session
1 June 2025
2:41pm
|
|
Lu, S
|
Savolitinib (Savo) combined
with osimertinib (osi) versus
chemotherapy (chemo) in
EGFR-mutant (EGFRm) and
MET-amplification (METamp)
advanced NSCLC after disease
progression (PD) on EGFR
tyrosine kinase inhibitor (TKI):
Results from a randomized
phase 3 SACHI study.
|
Abstract #LBA8505
Oral Abstract Session
1 June 2025
9:48am
|
|
Levy, BP
|
Efficacy and CNS results from
a randomized subset of the
phase 2 SAVANNAH study
comparing savolitinib (savo) +
osimertinib (osi) combination
with savo + placebo (PBO).
|
Abstract #8513
Rapid Oral Abstract Session
2 June 2025
8:06am
|
|
Chaft JE
|
Neoadjuvant (neoadj)
osimertinib (osi) ±
chemotherapy (CT) vs CT
alone in resectable (R)
epidermal growth factor
receptor-mutated (EGFRm)
NSCLC: NeoADAURA.
|
Abstract #8001
Oral Abstract Session
2 June 2025
3:12pm
|
|
免疫肿瘤学与双特异性抗体
|
|
Janjigian, YY
|
Event-free survival in
MATTERHORN: a randomized,
phase 3 study of durvalumab
plus 5-fluorouracil, leucovorin,
oxaliplatin, and docetaxel
chemotherapy (FLOT) in
resectable
gastric/gastroesophageal
junction cancer (GC/GEJC).
|
Abstract #LBA5
Plenary Session
1 June 2025
3:13pm
|
|
Powles, T
|
Circulating tumor DNA (ctDNA)
in patients with muscle-invasive
bladder cancer (MIBC) who
received perioperative
durvalumab (D) in NIAGARA
|
Abstract #4503
Oral Abstract Session
1 June 2025
10:45am
|
|
Reck, M
|
Associations of post-surgical
MRD status with neoadjuvant
ctDNA dynamics, genomic
mutations, and clinical
outcomes in patients with
resectable NSCLC (R-NSCLC)
from the phase 3 AEGEAN trial.
|
Abstract #8009
Rapid Oral Abstract Session
1 June 2025
4:30pm
|
|
Barbie, DA
|
Clinical and molecular
characteristics of early
progressors (EPs) and long
-term progression-free survivors
(LTPs) from the phase 3
ADRIATIC trial of
consolidation durvalumab (D) vs placebo (P)
after concurrent
chemoradiotherapy (cCRT) in
limited-stage small-cell lung
cancer (LS-SCLC).
|
Abstract #8014
Rapid Oral Abstract Session
1 June 2025
5:12pm
|
|
Mayadev, J
|
Ultrasensitive detection and
tracking of circulating tumor
DNA (ctDNA) and association
with relapse and survival in
locally advanced cervical
cancer (LACC): Phase 3
CALLA trial analyses.
|
Abstract #5502
Oral Abstract Session
2 June 2025
8:48am
|
|
Westin, SN
|
Durvalumab plus
carboplatin/paclitaxel followed
by durvalumab with or without
olaparib as first-line treatment
for endometrial cancer:
Longitudinal changes in
circulating tumor DNA.
|
Abstract #5512
Rapid Oral Abstract Session
3 June 2025
8:30am
|
|
Erinjeri, JP
|
Outcomes by baseline tumor
burden using the 6-and-12
score in EMERALD-1: a phase
3 study of durvalumab (D) ±
bevacizumab (B) with transarterial
chemoembolization (TACE) in
embolization-eligible
unresectable hepatocellular
carcinoma (uHCC).
|
Abstract #4083
Poster Session
31 May 2025
9:00am
|
|
Cascone, T
|
Neoadjuvant durvalumab (D) +
chemotherapy (CT) + novel
anticancer agents and adjuvant
D ± novel agents in resectable
non-small-cell lung cancer
(NSCLC): Updated outcomes
from NeoCOAST-2.
|
Abstract #8046
Poster Session
31 May 2025
1:30pm
|
|
Zhou, J
|
First-line rilvegostomig (rilve)
plus chemotherapy (CTx) in
advanced biliary tract cancer
(BTC): Primary analysis of
GEMINI-Hepatobiliary substudy
2 Cohort A.
|
Abstract #4080
Poster Session
31 May 2025
9:00am
|
|
Xu, R
|
ARTEMIDE-Gastric01: a phase
3 randomized study of
rilvegostomig with
fluoropyrimidine and
trastuzumab deruxtecan (T-
DXd) as first-line (1L) treatment
for locally advanced or
metastatic HER2-positive
gastric or gastroesophageal
junction cancer (GC/GEJC).
|
Abstract #TPS4204
Poster Session
31 May 2025
9:00am
|
|
Mathias, C
|
ARTEMIDE-Lung03: a phase 3,
randomized, double-blind,
multicenter, global study of
rilvegostomig or
pembrolizumab in combination
with platinum-based
chemotherapy as first-line
treatment for patients with
metastatic non-squamous non-
small-cell lung cancer whose
tumors express PD-L1.
|
Abstract #TPS8653
Poster Session
31 May 2025
1:30pm
|
|
细胞疗法
|
|
Yoo, C
|
RHEA-1: First-in-human (FIH)
study of AZD9793, a first-in-
class CD8-guided T cell-
engager (TCE) for glypican-3-
positive (GPC3+) advanced or
metastatic hepatocellular
carcinoma (HCC).
|
Abstract #TPS4215
Poster Session
31 May 2025
9:00am
|
|
Kim, TM
|
Safety and Efficacy of
AZD0486, a CD19xCD3 T-cell
Engager, in Relapsed or
Refractory Diffuse Large B-cell
Lymphoma.
|
Abstract #7046
Poster Session
1 June 2025
9:00am
|
|
Shadman, M
|
TITANium: An open-label,
global multicenter Phase 1/2
study of AZD5492, a first-in-
class subcutaneous CD8-
guided tri-specific T-cell
engager (TCE), in patients (pts)
with relapsed or refractory (r/r)
B-cell malignancies.
|
Abstract #TPS7091
Poster Session
1 June 2025
9:00am
|
|
Le Gouill, S
|
SOUNDTRACK-E: A Phase 1/2
Open-label Multicenter Study to
Evaluate the Safety and
Efficacy of AZD0486
Monotherapy or Combination
Therapy in Patients With
Mature B-cell Malignancies.
|
Abstract #TPS7083
Poster Session
1 June 2025
9:00am
|
|
罕见病药物
|
|
Chen, AP
|
Efficacy and safety of
selumetinib in adults with
neurofibromatosis type 1 (NF1)
and symptomatic, inoperable
plexiform neurofibroma (PN):
Primary analysis of KOMET
(NCT04924608), a Phase 3,
international, randomized,
placebo-controlled study.
|
Abstract #3014
Rapid Oral Abstract Session
2 June 2025
8:00am
|
